Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

levonorgestrel Articles

Good 1st-half sales and profits at Schering AG

28 July 2000

MCA reviews Schering's request for OTC Levonelle 2

25 May 2000

Call to block Wyeth's ad campaign in Canada for Alesse contraceptive

10 May 2000

New emergency contraception OKed in the UK

16 December 1999

Wyeth-Ayerst launches OC in Japan

9 September 1999

Wal-Mart won't sell Preven contraceptive

19 May 1999

Norplant trial collapses

11 February 1999

Europe/US sales offset Asian crisis at Schering

9 February 1999

US FDA makes progress, says their own product review record for 1998

29 January 1999

Phase III for emergency contraceptive

21 December 1998

First Emergency Contraceptive Cleared In USA

10 September 1998

Yuzpe Topped By Progestin Morning-After Pill

11 August 1998

Berlex' Levlite Approved In USA

16 July 1998

Schering AG: No Plans To Take PC4 From POM To P

17 June 1998

FDA Clears Wyeth-Ayerst's Alesse

7 April 1997

Schering AG Launches New HRT Patch In UK

17 March 1997

CPMP Position On 3rd Generation Contraceptives

3 February 1997

Dutch Government Reimbursement Blacklist Rises To 35

9 December 1996

Solid 3rd Qtr Growth For Large Pharma Cos

31 October 1994

AHP Bid For Cyanamid Will Broaden Product Range

15 August 1994

INTRA-UTERINE DEVICE COULD BE A BREAKTHROUGH

4 April 1994

NORPLANT LAUNCHED IN UK

25 October 1993

AMERICAN HOME: FINALLY A PHARMA COMPANY

7 December 1992

FRANCE LOWERS ORAL CONTRACEPTIVE PRICES

13 January 1992

Showing 101-124 of 124 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS